Uncategorized

Visus Therapeutics Announces $36 Million Series A Financing to Advance Development of Novel Presbyopia-Correcting Eye Drop

by Business Wire • 2021/03/09 • 0 Comments

SEATTLE--(BUSINESS WIRE)--Visus Therapeutics announces a $36 million Series A financing round to advance the development of BRIMOCHOL, its novel presbyopia-correcting eye drop

Full Story →

← Improving Structural Heart Disease Care: Interview with Joel Portice, egnite CEO

The Case for Stand-alone MIGS Gets Stronger →

Post navigation